Asklepios BioPharmaceutical (AskBio) has formed a strategic partnership with Belief BioMed (BBM) to develop new gene therapies using liver-targeted approaches. BBM, a China-based biotech company, specializes in viral vector technology and the development of gene therapies for severe conditions. This partnership will allow both companies to pool their expertise, with AskBio focusing on global science advancements and BBM offering its advanced capsid technology and gene therapy manufacturing capabilities.
BBM’s innovative work in viral vector development has positioned the company as a leader in China, where it recently submitted the first-ever gene therapy application for haemophilia B to the Chinese regulatory authority. AskBio's Chief Scientific Officer Mansuo Shannon expressed optimism about the collaboration, emphasizing BBM’s advanced technology and its potential to support AskBio's gene therapy goals.
This new partnership marks a significant step in AskBio’s strategy to expand its gene therapy portfolio. With Bayer’s backing and recent partnerships, such as the 2023 research agreement with ReCode Therapeutics, AskBio aims to push forward the next generation of gene therapies for patients worldwide.
Click here to read the original news story.